copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
AstraZeneca | Cafepharma AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
AstraZeneca | Cafepharma AstraZeneca’s quarterly revenue crossed the $15-billion mark for the first time, giving renewed hope to the company's target of reaching $80 billion in annual sales by the end of the decade "The strong underlying momentum across our business…sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition," remarked CEO Pascal Soriot on Thursday
Imfinzi | Cafepharma AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
Fasenra | Cafepharma AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD
baxdrostat | Cafepharma AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year
Cafepharma News Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends